Vaccination News Home Page

http://www3.interscience.wiley.com/cgi-bin/abstract/99017080/START

Wiley InterScience Home Page Personal Home Page Journal Finder Book Finder Search Wiley Interscience Reference Works Help Contact Us Logout
Article Abstract All Journals Previous Article Next Article acronym finder
About this Journal  

Online ISSN: 1096-911X    Print ISSN: 0098-1532
Medical and Pediatric Oncology
Volume 39, Issue 6, 2002. Pages: 554-557

Published Online: 9 Oct 2002
 

Copyright © 2002 Wiley-Liss, Inc.


Add to your Hot Article list
Enhanced Abstract Available
Article's Full Text in PDF
No HTML Full Text Available

 Research Article
 

SEER update of incidence and trends in pediatric malignancies: Acute lymphoblastic leukemia
Dawn Elizabeth McNeil, MD 1 *, Timothy R. Coté, MD, MPH 2, Limin Clegg, PhD 2, Alvin Mauer, MD 3
1National Cancer Institute, Division of Cancer Epidemiology and Genetics, Genetic Epidemiology Branch, Rockville, Maryland
2National Cancer Institute, Division of Cancer Control and Population Sciences, Cancer Statistics Branch, Rockville, Maryland
3Division of Hematology/Oncology, University of Tennessee, Memphis, Tennessee
 
email: Dawn Elizabeth McNeil (mcneile@mail.nih.gov)

*Correspondence to Dawn Elizabeth McNeil, Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI/NIH/EPS room 7125, 6120 Executive Boulevard, MSC 7236, Bethesda, MD 20892-7236.

 

Keywords
acute lymphoblastic leukemia (ALL) • epidemiology • SEER

 

Abstract

Background
Acute lymphoblastic leukemia (ALL) represents the most common malignancy of childhood. Its incidence peaks in children just before school entry age; i.e., in 2-3 year olds. It is known to be more common in white children in the USA; the incidence is also higher in boys than girls.

Procedure
We reviewed the 5,379 cases of ALL among persons under 20 years of age in the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database.

Results
The overall incidence of ALL was 26/106 person-years between 1973 and 1998, but increased from 19/106 person-years in 1973-77 to 28/106 person-years in 1993-98 (P < 0.0001). Rates were 44% higher among Whites compared to Blacks (27/106 person-years vs. 15/106 person-years, P < 0.0001). In 1992-1998, the incidence rate for Hispanics was 43/106 person-years, significantly higher than non-Hispanics (28/106, P < 0.0001). White children with ALL had better 5-year survival rates than Black children with ALL (71% vs. 58%, P < 0.0001), and 5-year survival was poorest among black males.

Conclusions
ALL incidence has increased over the examined 25-year period. The rate in US whites is higher than that of US Blacks, and the rates in the Hispanic subgroup are the highest of all. While the median survival period is now more than 10 years overall, the 5-year survival rate remains poor for Black males under 4 years of age. Socioeconomic factors do not account for this difference, which may relate to ALL subtype distribution. Med Pediatr Oncol 2002;39:554-557. © 2002 Wiley-Liss, Inc.

Received: 6 February 2002; Accepted: 30 April 2002

 

Digital Object Identifier (DOI)


10.1002/mpo.10161  About DOI


 

References are available in the Enhanced Abstract


Additional Information


 


 

[Wiley InterScience Home Page] [Personal Home Page] [Journal Finder] [Book Finder] [Search Wiley InterScience] [Reference Works] [Help] [Contact Us][Logout]

Wiley InterScience is a member of CrossRef

CrossRef
 


Copyright © 1999-2002 by John Wiley & Sons, Inc. All rights reserved.
 

 

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.